Trial Profile
A randomized, open label, two-way crossover study investigating the relative bioavailability of a single 5 mg dose of everolimus administered as either 5x1 mg everolimus intact tablets or 5x1 mg everolimus tablets suspended in 30 mL of water to healthy subjects
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 24 Jul 2017
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Angiomyolipoma; Astrocytoma; Bladder cancer; Breast cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Endometrial hyperplasia; Glioma; Head and neck cancer; Hodgkin's disease; Liver cancer; Multiple myeloma; Neuroendocrine tumours; Neurofibromatosis 2; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Plexiform neurofibroma; Prostate cancer; Renal cell carcinoma; Sarcoma; Solid tumours; Tuberous sclerosis
- Focus Pharmacokinetics
- Sponsors Novartis
- 19 May 2016 New trial record